The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given. “In an era of ever increasing prescription drug costs, this bill is an important step to ensure 340B hospitals subject to the orphan drug exclusion can obtain lifesaving drugs at a much needed discount so they can stretch limited resources to better serve their communities,” AHA wrote in a letter of support to Reps. Peter Welch, D-V.T., and David McKinley, R-W.Va., the bill’s sponsors.

Related News Articles

Headline
The House of Representatives last night voted 233-188 along party lines to pass a $1.5 trillion bill (H.R. 2) introduced by Democratic leaders to rebuild…
Perspective
As James Madison wrote in the First Amendment of our Bill of Rights, we have the right to “petition the government for a redress of grievances.” We also have…
Headline
The Federal Communications Commission’s Rural Health Care Program will carry forward up to $197.98 million in unused funds from prior years to increase…
Headline
The Administration for Community Living July 1 at 2 p.m. ET will host a webinar featuring leaders sharing COVID19-related and other resources and research to…
Perspective
Expanding access to telehealth services to provide much more patient-centered, convenient care. Creating additional health care workforce capacity and avoiding…
Chairperson's File
Among the many lessons we have learned from the COVID-19 pandemic is the critical importance of leadership. Across our nation, health care leaders — whether…